Navigating New EU And German Veterinary Regulations: Key Impacts And Opportunities

Introduction: Transforming the European Veterinary Regulatory Landscape

The implementation of EU Regulation (EU) 2019/6 on Veterinary Medicinal Products and Germany’s Veterinary Medicinal Products Act (TAMG) marks a significant transformation in the regulatory framework governing veterinary pharmaceuticals across Europe. These regulations, enforced since January 28, 2022, aim to harmonize standards, strengthen pharmacovigilance systems, and address critical public health concerns such as antimicrobial resistance (AMR).

Regulatory oversight is coordinated through European authorities such as the European Medicines Agency, ensuring consistent implementation across EU member states.

While these reforms enhance market transparency, product safety, and cross-border trade, they also introduce complex compliance requirements in GMP, GDP, pharmacovigilance, and data reporting systems.

Maven Regulatory Solutions supports organizations in navigating these evolving requirements with expertise in EU veterinary regulatory affairs, toxicology, and compliance strategy, enabling efficient and compliant market access.

Regulatory Objectives: Advancing Animal Health and Public Safety

The new EU and German veterinary frameworks are designed to support:

• Harmonized regulatory standards across the EU single market 
• Improved availability and accessibility of veterinary medicinal products 
• Stronger pharmacovigilance and traceability systems 
• Proactive measures to mitigate antimicrobial resistance (AMR) 

Healthy livestock and companion animals are critical for sustainable agriculture, food safety, and global public health, making regulatory compliance essential for industry stakeholders.

Key Provisions of EU Regulation (EU) 2019/6

1. Harmonization of the European Veterinary Market

The regulation introduces a unified framework that reduces administrative fragmentation and enhances market access.

Key Highlights:

• Standardized marketing authorization procedures 
• Simplified mutual recognition and decentralized processes
• Centralized EU veterinary medicinal product database (Articles 55 & 73) 
• Enhanced access to pharmacovigilance and product data 

2. Antimicrobial Resistance (AMR) Control Measures

A cornerstone of Regulation 2019/6 is the strict control of antimicrobial usage.

Critical Provisions:

• Restriction of critically important antimicrobials for human use (Article 37) 
• Limited prophylactic use of antibiotics (Article 107) 
• Mandatory electronic reporting of antimicrobial consumption (Article 58) 

3. Classification of Veterinary Medicinal Products

Products are categorized to ensure appropriate access and control:

• Prescription-Only Medicines (POM-V)
• Non-prescription / Over the Counter (OTC) products 

Key Features of EU Regulation (EU) 2019/6

German Veterinary Medicinal Products Act (TAMG): National-Level Enhancements

Germany’s TAMG introduces stricter national provisions that complement EU regulation, with a strong focus on traceability, antibiotic stewardship, and digital reporting.

Key National Requirements

1. Antibiotic Usage Restrictions

• 7-day limit for antibiotics in food-producing animals 
• 31-day limit for other veterinary medicinal products 

2. Mandatory Electronic Reporting

• Reporting of antibiotic use via HI-Tier-TAM database 
• Applies to commercial farms and hobby animal keepers 

3. Enhanced Documentation & Traceability

• Detailed prescription records 
• Mandatory digital record-keeping systems 
• Real-time compliance monitoring 

EU Regulation vs German TAMG

GMP, GDP, and Qualified Person (QP) Requirements

The updated regulations significantly strengthen Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) requirements.

Key Changes

• Separate manufacturing authorizations for veterinary products 
• External laboratories must hold manufacturing licenses 
• Mandatory appointment of a Qualified Person (QP) 
• Expanded QP qualifications in pharmacy, veterinary science, or life sciences 

GMP & QP Compliance Requirements

Emerging Trends in EU Veterinary Regulations

• Expansion of digital regulatory systems and e-submissions
• Increased focus on One Health approach integrating animal-human health 
• Strengthened environmental risk assessment (ERA) requirements 
• Adoption of real-world data (RWD) and analytics in pharmacovigilance 
• Enhanced enforcement of antimicrobial stewardship programs

Maven Regulatory Solutions: Comprehensive EU Veterinary Compliance Support

Maven Regulatory Solutions provides end-to-end regulatory consulting services tailored to EU and German veterinary frameworks.

Core Expertise

1. Dossier Preparation & Marketing Authorization

• EU-compliant veterinary dossier preparation 
• Support for centralized, decentralized, and mutual recognition procedures 

2. Pharmacovigilance & Regulatory Reporting

• EU database submissions 
• HI-Tier-TAM reporting compliance 
• Signal detection and safety monitoring 

3. GMP/GDP Compliance & QP Services

• Manufacturing license support 
• GDP audits and compliance systems 
• Qualified Person training and certification 

4. Toxicological & Environmental Risk Assessment

• Safety and efficacy evaluation 
• AMR risk assessment 
• Environmental impact studies 

5. Regulatory Intelligence & Strategy

• Continuous monitoring of EU veterinary regulatory updates
• Risk-based compliance strategies 
• Market access acceleration 

Opportunities for Industry Stakeholders

Despite increased regulatory complexity, these frameworks create opportunities for:

• Innovation in veterinary pharmaceuticals 
• Expansion into EU single market with harmonized rules 
• Improved product quality and global competitiveness 
• Leadership in antimicrobial resistance mitigation 

Conclusion

The introduction of EU Regulation (EU) 2019/6 and Germany’s TAMG has redefined the regulatory landscape for veterinary medicinal products. While these regulations introduce stringent compliance requirements, they also create a structured and transparent ecosystem that supports innovation, safety, and global market access.

With deep expertise in veterinary regulatory affairs, toxicology, and compliance strategy, Maven Regulatory Solutions serves as a trusted partner for navigating these complexities and achieving successful product registration in Europe.

Frequently Asked Questions

1. What is EU Regulation 2019/6?

A comprehensive framework governing authorization, distribution, and pharmacovigilance of veterinary medicinal products in the EU.

2. What is TAMG in Germany?

Germany’s national law introducing stricter antibiotic controls, reporting requirements, and traceability measures.

3. How does AMR impact veterinary regulations?

AMR drives restrictions on antibiotic use and mandates detailed reporting and monitoring systems.

4. What are GMP requirements for veterinary products?

They include manufacturing authorization, quality control systems, and Qualified Person oversight.